Nigeria has introduced Lenacapavir, a long-acting HIV prevention injection administered just twice a year, marking a major milestone in the country’s fight against HIV/AIDS.
Lenacapavir is designed to provide extended protection against HIV infection with only two doses annually, offering a new option for individuals at risk who may struggle with daily preventive medication adherence. Health experts say the introduction of the drug could significantly improve prevention outcomes, particularly among high-risk populations.
A Game-Changer in HIV Prevention
Unlike daily oral pre-exposure prophylaxis (PrEP), Lenacapavir requires just two injections per year, potentially increasing convenience and compliance. Public health officials describe the development as a breakthrough that could strengthen Nigeria’s HIV prevention strategy.
Nigeria remains one of the countries with a high HIV burden in sub-Saharan Africa. Expanding access to innovative prevention tools is seen as critical to reducing new infections and achieving national and global HIV elimination targets.
What This Means for Nigerians
Expanded prevention options for at-risk individuals Reduced reliance on daily pills Potential improvement in adherence and protection rates Strengthened national HIV response efforts
Health authorities are expected to provide further details on eligibility, rollout plans, distribution centers, and pricing in the coming days.
